- Home
- ESTA vs GLUE Comparison
ESTA vs GLUE Comparison
Compare ESTA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTA | GLUE |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESTA | GLUE |
|---|---|---|
| Price | $69.40 | $19.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $86.86 | $32.00 |
| AVG Volume (30 Days) | 485.3K | ★ 646.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $61,208,000.00 | ★ $123,672,000.00 |
| Revenue This Year | $28.05 | N/A |
| Revenue Next Year | $26.21 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | ★ 76.49 | 63.54 |
| 52 Week Low | $33.35 | $4.09 |
| 52 Week High | $83.31 | $25.77 |
Technical Indicators
Market Signals| Indicator | ESTA | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 56.07 |
| Support Level | $68.75 | $17.38 |
| Resistance Level | $74.41 | $20.24 |
| Average True Range (ATR) | 3.76 | 0.97 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 46.98 | 55.21 |
Price Performance
Historical ComparisonAbout ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).